Statera Biopharma is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Co.'s proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia. Co.'s product candidate in this field is entolimod, an immune-stimulatory agent, which Co. is developing as a radiation countermeasure and other indications in radiation oncology. The STAB stock yearly return is shown above.
The yearly return on the STAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the STAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|